Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -89.16% is 35% above its 5-year average of -136.47%, near the high end of its 5-year range (-241.56%–-65.81%).
7.05% below its 12-month average of -83.29%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -80.29%.
EBITDA MARGIN
-89.16%
EBITDA MARGIN AVG TTM
-83.29%
EBITDA MARGIN AVG 3Y
-91.57%
EBITDA MARGIN AVG 5Y
-136.47%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.05%
CURRENT VS 3Y AVG
+2.63%
CURRENT VS 5Y AVG
+34.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Market Cap
$43.87M
EBITDA Margin
-131.42%
TTM Avg
-148.69%
3Y Avg
-221.80%
5Y Avg
-210.76%
Market Cap
$43.59M
EBITDA Margin
-376.33%
TTM Avg
-387.64%
3Y Avg
-608.18%
5Y Avg
-1395.53%
Market Cap
$43.51M
EBITDA Margin
14.14%
TTM Avg
17.13%
3Y Avg
-2.79%
5Y Avg
-117.76%
Market Cap
$45.21M
EBITDA Margin
-3807.96%
TTM Avg
-2001.11%
3Y Avg
-1442.90%
5Y Avg
-1442.90%
Market Cap
$44.75M
EBITDA Margin
-148.02%
TTM Avg
-167.05%
3Y Avg
-193.51%
5Y Avg
-252.90%
Market Cap
$42.12M
EBITDA Margin
-0.99%
TTM Avg
4.72%
3Y Avg
-25.09%
5Y Avg
-32.37%
Market Cap
$46.73M
EBITDA Margin
-24194.20%
TTM Avg
-24194.20%
3Y Avg
-24194.20%
5Y Avg
-24194.20%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CVRx, Inc. (CVRX) | $44.85M | -89.16% | -83.29% | -91.57% | -136.47% |
| Rapid Micro Biosystems, Inc. (RPID)vs › | $43.87M | -131.42% | -148.69% | -221.80% | -210.76% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.59M | -376.33% | -387.64% | -608.18% | -1395.53% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.51M | 14.14% | 17.13% | -2.79% | -117.76% |
| Werewolf Therapeutics, Inc. (HOWL)vs › | $45.21M | -3807.96% | -2001.11% | -1442.90% | -1442.90% |
| DarioHealth Corp. (DRIO)vs › | $44.75M | -148.02% | -167.05% | -193.51% | -252.90% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.12M | -0.99% | 4.72% | -25.09% | -32.37% |
| Precipio, Inc. (PRPO)vs › | $41.92M | 2.29% | -7.32% | -44.00% | -66.61% |
| Instil Bio, Inc. (TIL)vs › | $46.73M | -24194.20% | -24194.20% | -24194.20% | -24194.20% |
| Veru Inc. (VERU)vs › | $41.81M | -217.02% | -395.41% | -245.06% | -171.96% |
Gross Margin
86.6%
EBITDA Margin
-89.2%
Operating Margin
-90.5%
Net Margin
-84.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -80.29% |
| 2026-03-31 | -80.95% |
| 2025-12-31 | -68.64% |
| 2025-09-30 | -82.19% |
| 2025-06-30 | -104.37% |
| 2025-03-31 | -107.33% |
| 2024-12-31 | -65.81% |
| 2024-09-30 | -96.03% |
| 2024-06-30 | -117.15% |
| 2024-03-31 | -205.21% |
| 2023-12-31 | -84.32% |
| 2023-09-30 | -89.34% |
| 2023-06-30 | -122.37% |
| 2023-03-31 | -150.81% |
| 2022-12-31 | -158.18% |
| 2022-09-30 | -161.64% |
| 2022-06-30 | -217.03% |
| 2022-03-31 | -241.56% |
| 2021-12-31 | -238.71% |
| 2021-09-30 | -213.52% |
| 2021-06-30 | -180.44% |
| 2021-03-31 | -146.29% |
| 2020-12-31 | -101.15% |
| 2020-09-30 | -303.41% |
| 2020-06-30 | -243.36% |
| 2020-03-31 | -189.76% |
